Role of Immunomarkers in the Clinicopathological Analysis of Unicystic Ameloblastoma

Table 2

Immunoprofiles of Ki-67, CD34, MMP-9, and MMP-2 in cystic ameloblastoma.

Pathological type	Case no.	Ki-67 LI** (%)	MVD*** (per HPF)	MMP-2 expression*	MMP-9 expression*
Luminal	2	5.59	18.3	−	−
	7	6.25	29.6	+	+
	8	0.6	21.3	+	−
	10	2.33	32.3	−	−
	12	1.95	31.6	+	+
	16	1.45	21	+	+
Intraluminal	3	3.95	36.3	++	++
	4	6.2	37.3	++	++
	6	1.85	42.3	++	++
	9	4.56	20.3	++	++
	17	2.85	47.3	++	++
	18	5.97	21	++	++
Mural	1	9.13	52	++	++
	5	4.78	47	+++	+++
	11	2.72	22	+++	++
	13	4.43	54	+++	+++
	14	3.08	37	+++	+++
	15	3.65	39	+++	+++

∗Immunohistochemical reactivity for MMP-2 and MMP-9: (−) negative, (+) weak positive, (++) moderate positive, and (+++) strong positive.
∗∗Ki-67 LI: Ki-67 labeling index.
∗∗∗MVD: microvessel density.